2-(4-formyl-2-methoxyphenoxy)-N-(pyridin-2-yl)acetamide | 1224637-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-formyl-2-methoxyphenoxy)-N-(pyridin-2-yl)acetamide
• CAS: 1224637-19-7
• 化学式: C₁₅H₁₄N₂O₄
• 分子量: 286.287
• InChiKey: BCWISFYMGZQLSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  21.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  77.52
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  罗丹宁 、 2-(4-formyl-2-methoxyphenoxy)-N-(pyridin-2-yl)acetamide 在 哌啶 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 0.5h， 生成 2-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-N-pyridin-2-ylacetamide
  参考文献：
  名称：

  Novel glitazones: Design, synthesis, glucose uptake and structure–activity relationships

  摘要：

  Glitazones are known to exhibit antihyperglycemic activity by decreasing peripheral insulin resistance. In the present study, we have designed some novel glitazones based on the structure-activity relationships as possible PPAR-gamma agonists. The manually designed glitazones were synthesized by using the appropriate synthetic schemes and screened for their in vitro antihyperglycemic activity by estimating glucose uptake by rat hemi-diaphragm, both in the absence and in the presence of external insulin. Some of the glitazones exhibited good antihyperglycemic activity in presence of insulin. Illustration about their design, synthesis, evaluation, and structure-activity relationships is described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.125
• 作为产物：
  描述：

  2-氨基吡啶 在 potassium carbonate 、 三乙胺 作用下， 以 氯仿 、 丙酮 为溶剂， 反应 42.5h， 生成 2-(4-formyl-2-methoxyphenoxy)-N-(pyridin-2-yl)acetamide
  参考文献：
  名称：

  Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure–activity relationships

  摘要：

  We report a series of new glitazones incorporated with phenylalanine and tyrosine. All the compounds were tested for their in vitro glucose uptake activity using rat-hemidiaphragm, both in presence and absence of insulin. Six of the most active compounds from the in vitro screening were taken forward for their in vivo triglyceride and glucose lowering activity against dexamethazone induced hyperlipidemia and insulin resistance in Wistar rats. The liver samples of rats that received the most active compounds, 23 and 24, in the in vivo studies, were subjected to histopathological examination to assess their short term hepatotoxicity. The investigations on the in vitro glucose uptake, in vivo triglyceride and glucose lowering activity are described here along with the quantitative structure-activity relationships. (C) 2012 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2012.08.002

文献信息

• Synthesis, Spectral Investigations, Biological Studies, and In Silico Approach of Vanillin Heterocyclic Acetamides
  作者：Manikkam Bharathi、S. Shreedevi、Rajendran Sribalan

  DOI：10.1134/s1068162024120550

  日期：2024.6

  sequence of biologically active vanillin acetamides bearing heterocyclic moiety (VHAs) specifically vanillin isoniazid acetamide (VISO), vanillin-2-pyridine acetamide (V2PR), vanillin-4-pyridine acetamide (V4PR), and vanillin-2-pyrimidine acetamide (V2PM) are synthesized and methodically characterized by spectroscopic techniques such as Nuclear Magnetic Resonance (1H and 13C NMR), Electrospray Ionization

  抽象的 目的：一系列带有杂环基团 (VHA) 的具有生物活性的香草醛乙酰胺，特别是香草醛异烟肼乙酰胺 (VISO)、香草醛-2-吡啶乙酰胺 (V2PR)、香草醛-4-吡啶乙酰胺 (V4PR) 和香草醛-2-嘧啶乙酰胺(V2PM) 通过核磁共振（ 1 H 和 13 C NMR）、电喷雾电离质量、傅里叶变换红外和紫外-可见光谱等光谱技术进行合成和系统表征。此外，还检查VHA的体外生物活性，例如通过蛋白质抗变性抗炎、通过酶抑制方法抗糖尿病，并将体外结果与参考药物联系起来。方法：在室温下向中间体TBTU和三甲胺的乙腈溶液中加入。将反应混合物搅拌30分钟，然后添加相应的胺。将反应混合物搅拌4小时并将反应混合物用乙酸乙酯萃取。溶剂蒸发产生VHA。 VHA 的抗炎活性通过牛血清白蛋白变性技术进行测试。使用 α-淀粉酶抑制方法测试 VHA 的抗糖尿病活性。结果与讨论：所设计的 VHA 已成功合成，并通过必要的光谱技术（